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Correction
After publication of this work [1], we became aware of a
typographical error. The term dysphagia inadvertently
replaced the term dysarthria in two instances. Dysarthria
was statistically significantly worsened at week 80 com-
pared to baseline, whereas there was only a statistical
trend (p = 0.10) for dysphagia at week 80 compared to
baseline. Dysphagia continues to be an issue in patients
with Huntington Disease and was reported as an adverse
event in this study. Therefore, clinicians who prescribe
tetrabenazine should still monitor their patients for wor-
sening swallowing, but the worsening was not statisti-
cally different in those who completed this trial. No
further studies of tetrabenazine in Huntington Disease
have been completed since the publication of this study.
Dysarthria should be replaced for dysphagia in two
places and the manuscript should read as follows:
Abstract, page 1:
Results: Parkinsonism and dysarthria scores were sig-
nificantly increased at week 80 compared to baseline.
Discussion, page 8:
Although parkinsonism and dysarthria were increased
in subjects at week 80, this finding was likely a result of
the natural progression of disease.
The other uses of the terms dysarthria and dysphagia
in the manuscript are correct. We regret the error and
any inconvenince it may have caused.
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